Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. reduced its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 14.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 31,500 shares of the biotechnology company’s stock after selling 5,500 shares during the quarter. D.A. Davidson & CO.’s holdings in Heron Therapeutics were worth $69,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Point72 Asset Management L.P. purchased a new stake in shares of Heron Therapeutics in the 4th quarter valued at approximately $4,706,000. Tang Capital Management LLC increased its position in shares of Heron Therapeutics by 15.7% in the 4th quarter. Tang Capital Management LLC now owns 2,140,271 shares of the biotechnology company’s stock valued at $3,275,000 after purchasing an additional 290,271 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock valued at $1,692,000 after purchasing an additional 9,418 shares during the last quarter. Bank of America Corp DE increased its position in shares of Heron Therapeutics by 9.5% in the 4th quarter. Bank of America Corp DE now owns 1,046,790 shares of the biotechnology company’s stock valued at $1,602,000 after purchasing an additional 90,862 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Heron Therapeutics by 2.2% in the 4th quarter. Northern Trust Corp now owns 1,011,756 shares of the biotechnology company’s stock valued at $1,548,000 after buying an additional 21,769 shares during the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Trading Down 1.8%

NASDAQ:HRTX opened at $2.18 on Friday. The firm has a 50-day moving average price of $2.04 and a two-hundred day moving average price of $1.98. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.73. The company has a market capitalization of $332.58 million, a P/E ratio of -36.33 and a beta of 1.18.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to analysts’ expectations of $37.08 million. On average, equities research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

HRTX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th. Wall Street Zen upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. Finally, HC Wainwright assumed coverage on shares of Heron Therapeutics in a research note on Monday, June 9th. They set a “buy” rating and a $6.00 price target for the company.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.